Nektar Therapeutics (NKTR) Non-Current Assets (2010 - 2026)

Nektar Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $174.2 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 561.77% year-over-year to $174.2 million in Q1 2026; TTM through Mar 2026 was $229.3 million, a 65.56% increase from a year earlier, with the FY2025 full-year figure at $14.1 million, down 66.77% from the prior year.
• Non-Current Assets climbed to $174.2 million in Q1 2026 per NKTR's latest filing, from $14.1 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $290.7 million in Q1 2022 and bottomed at $14.1 million in Q4 2025.
• The 5-year median for Non-Current Assets is $53.2 million (2023), against an average of $88.9 million.
• Across the five-year window, Non-Current Assets plunged 76.19% in 2023 and surged 561.77% in 2026, its largest moves.
• Year by year, Non-Current Assets stood at $164.6 million in 2022, then slumped by 59.1% to $67.3 million in 2023, then sank by 36.79% to $42.6 million in 2024, then tumbled by 66.77% to $14.1 million in 2025, then jumped by 1132.18% to $174.2 million in 2026.
• Per Business Quant, the three latest NKTR Non-Current Assets figures stand at $174.2 million (Q1 2026), $14.1 million (Q4 2025), and $20.0 million (Q3 2025).